Topline data of two ongoing COVID-19 studies with KB109 expected in the first quarter of 2021
Study KB295 in ulcerative colitis patients stays on track with Topline data planned for mid-2021
LEXINGTON, Mass., March 3, 2021 (GLOBE NEWSWIRE) – Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated chemistry-driven approach to targeting the microbiome to treat disease and improving human health, today released financial results for the fourth quarter and the full year ended December 31, 2020.
“In 2020, our company achieved several important financial and clinical milestones that have positioned us for a productive and busy year ahead. Supported by our recently completed funding, we are starting the year with a strong cash position, enabling continued growth and expansion of our extensive Microbiological Metabolic Therapies (MMTTM) -based pipeline, ”said Dan Menichella, President and Chief Executive Officer. from the direction of Kaleido. “Recently, we reported positive interim results from K031, one of two ongoing uncontrolled IND clinical studies in KB109 evaluating outpatients with mild to moderate COVID-19 disease. The results demonstrated favorable safety and tolerability as well as evidence of clinical benefit for subjects reporting one or more more comorbidities. We look forward to reporting data of our two KB109 studies in the first quarter of 2021, including the entire study population in study K031 as well as the main results of study K032…
News Highlights Finance
- Headline: Kaleido Biosciences Reports Fourth Quarter and Fiscal 2020 Financial Results
- Check all news and articles from the Finance news updates.